FIXX · Homology Medicines, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $3.21M | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.22M | - | $3.56M | $5.16M | $7.12M | - | $14.35M | $13.41M | $9.84M | - |
| SG&A | $4.50M | - | $4.02M | $4.01M | $5.10M | - | $4.47M | $4.51M | $5.00M | - |
| Total Operating Expenses | $7.72M | - | $7.58M | $9.17M | $12.23M | - | $18.81M | $17.92M | $14.84M | - |
| D&A | $90.0K | - | $100.0K | $100.0K | $119.0K | - | - | - | $123.0K | - |
| Operating Income | ($7.72M) | - | ($7.58M) | ($9.17M) | ($12.23M) | - | ($18.81M) | ($17.92M) | ($14.84M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($7.61M) | - | ($7.39M) | ($9.49M) | ($11.03M) | - | ($17.59M) | ($16.98M) | $1.03M | - |
| EPS - Basic | ($0.54) | - | ($0.60) | ($0.78) | ($0.90) | - | ($1.46) | ($1.42) | $1.03 | - |
| EPS - Diluted | ($0.54) | - | ($0.60) | ($0.78) | ($0.90) | - | ($1.46) | ($1.42) | ($6.33) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.75M | $48.30M | $49.04M | $54.83M | $65.48M | $77.97M | $89.08M | $97.66M | $115.51M | $39.27M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $653.0K | $879.0K | $973.0K | $910.0K | $2.71M | $2.99M | $1.26M | $2.48M | $4.96M | $3.23M |
| Current Assets | $57.20M | $55.05M | $50.81M | $58.32M | $68.63M | $81.88M | $93.90M | $111.62M | $138.04M | $83.91M |
| Total Assets | $63.67M | $61.78M | $57.78M | $66.12M | $79.07M | $92.33M | $104.54M | $124.21M | $152.33M | $84.56M |
| Current Liabilities | $10.67M | $11.35M | $11.11M | $11.53M | $14.58M | $16.46M | $14.38M | $17.19M | $32.95M | $11.57M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $17.36M | $19.76M | $76.23M | $78.35M | $83.08M | $86.66M | $86.25M | $90.70M | $103.56M | $11.57M |
| Stockholders' Equity | $46.31M | $42.01M | $4.00M | ($12.23M) | ($4.01M) | $5.67M | $18.30M | $33.51M | $48.77M | $72.99M |
| Retained Earnings | ($212.60M) | ($204.99M) | ($262.72M) | ($255.33M) | ($245.84M) | ($234.81M) | ($220.63M) | ($203.03M) | ($186.05M) | ($542.10M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.34M) | - | - | - | ($12.48M) | - | - | - | ($14.55M) | - |
| Investing Cash Flow | $0 | - | - | - | $0 | - | - | - | $97.0K | - |
| Financing Cash Flow | $8.80M | - | - | - | - | - | - | - | $99.35M | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($14.55M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | -559.1% | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | -529.7% | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | -14.14 | - |
| R&D / Revenue | - | - | - | - | - | - | - | 418.4% | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | 140.7% | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 0.0% | - |
| Return on assets | -11.9% | - | -12.8% | -14.4% | -14.0% | - | -16.8% | -13.7% | 0.7% | - |
| Return on equity | -16.4% | - | -184.7% | 77.6% | 274.8% | - | -96.2% | -50.7% | 2.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.36 | 4.85 | 4.57 | 5.06 | 4.71 | 4.97 | 6.53 | 6.49 | 4.19 | 7.25 |
| Quick ratio | 5.36 | 4.85 | 4.57 | 5.06 | 4.71 | 4.97 | 6.53 | 6.49 | 4.19 | 7.25 |
| Cash ratio | 4.76 | 4.26 | 4.41 | 4.75 | 4.49 | 4.74 | 6.19 | 5.68 | 3.51 | 3.39 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.37 | 1.47 | 14.45 | -5.40 | -19.70 | 16.27 | 5.71 | 3.71 | 3.12 | 1.16 |
| Liabilities / Assets | 0.27 | 0.32 | 1.32 | 1.19 | 1.05 | 0.94 | 0.82 | 0.73 | 0.68 | 0.14 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.00 | 0.03 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | 805.4% | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | 13.6% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | 52.2% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 36.8% | - | 59.7% | 48.8% | 17.6% | - | 39.3% | 41.9% | 46.0% | - |
| Net income growth (YoY) | 31.0% | - | 58.0% | 44.1% | - | - | 46.6% | 51.6% | - | - |
| EPS growth (YoY) | 40.0% | - | 58.9% | 45.1% | 85.8% | - | -156.1% | -132.8% | -1166.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 44.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 640.3% | -78.1% | - | - | -92.2% | -79.3% | -71.9% | -67.9% | -59.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Homology Medicines against the 5 most active filers in the same SIC group.